Curis
CRIS · United States
Share price · CRIS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRIS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+24.3%
Nothing announced by CRIS that day or the session before.
- 13 Nov 2026-22.2%
- 9 Nov 2026-23.0%
- 4 Nov 2026+55.5%
Nothing announced by CRIS that day or the session before.
- 29 Oct 2026+20.8%
Nothing announced by CRIS that day or the session before.
- 16 Oct 2026-19.9%
- 15 Oct 2026-15.3%
Nothing announced by CRIS that day or the session before.
- 6 Jul 2026+1613.8%
- 29 Jun 2026+37.7%
- 26 Jun 2026+56.0%
Share of unusual movement by asset
For each asset, the share of CRIS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IRAK4Small molecule | Acute Myeloid LeukemiaNon-Hodgkin Lymphoma Relapsed/Refractory Acute Myeloid Leukemia, Primary Central Nervous System Lymphoma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
July 2027 (1)
What to watch
November 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | $5.6M | $8.1M-$5.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $6.7M | $5.6M+ <$0.1M short-term inv. | $8.6M-$9.7M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $6.5M | $16M | $24M-$9.0M operating cash flow | report ↗ |
| 2025-Q3 | $3.2M | $6.4M | $9.6M+ $0.1M short-term inv. | $7.7M-$5.6M operating cash flow | report ↗ |
| 2025-Q2 | $2.8M | $7.5M | $11M | $8.6M-$8.0M operating cash flow | report ↗ |
| 2025-Q1 | $2.4M | $8.5M | $21M+ <$0.1M short-term inv. | $11M-$7.3M operating cash flow | report ↗ |
| 2024-Q3 | $2.9M | $9.7M | $21M+ $0 short-term inv. | $10M-$5.9M operating cash flow | report ↗ |
| 2024-Q2 | $2.5M | $10M | $11M+ $18M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2024-Q1 | $2.1M | $9.6M | $31M+ $11M short-term inv. | $12M-$13M operating cash flow | report ↗ |
| 2023-Q3 | $2.8M | $10M | $25M+ $44M short-term inv. | $12M-$8.2M operating cash flow | report ↗ |
| 2023-Q2 | $2.2M | $10M | $20M+ $44M short-term inv. | $12M-$7.9M operating cash flow | report ↗ |
| 2023-Q1 | $2.3M | $9.1M | $32M+ $40M short-term inv. | $12M-$12M operating cash flow | report ↗ |
| 2022-Q3 | $2.8M | $11M | $30M+ $69M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2022-Q2 | $2.4M | $12M | $35M+ $73M short-term inv. | $16M-$12M operating cash flow | report ↗ |
| 2022-Q1 | $2.1M | $11M | $19M+ $102M short-term inv. | $16M-$17M operating cash flow | report ↗ |
| 2021-Q3 | $3.0M | $8.6M | $54M+ $76M short-term inv. | $11M-$9.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $9.4M | $28M | $5.6M+ <$0.1M short-term inv. | $1.9M-$27M operating cash flow | report ↗ |
For fiscal year 2025, Curis reported revenue of $9.44M, down 13.5% YoY, and R&D spend of $28.25M, down 26.7% YoY. Cash and equivalents were $5.61M as of December 31, 2025, and the company reported a net loss of $7.58M for the year.
Operationally, Curis continued development of emavusertib, presenting updated PCNSL data from the TakeAim Lymphoma study, initial SCNSL data, and MRD conversion data from the AML triplet study. The company initiated a Phase 2 CLL study of emavusertib with zanubrutinib, sold its Erivedge royalty interest in November 2025, and closed a January 2026 private placement with gross proceeds of up to $80.8M, including initial gross proceeds of $20.2M. Curis guided that its cash position plus the January 2026 PIPE proceeds should fund planned operations into the second half of 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $11M | $39M | $21M+ $0 short-term inv. | $11M-$40M operating cash flow | report ↗ |
| 2023-FY | $10M | $40M | $27M+ $30M short-term inv. | $12M-$38M operating cash flow | report ↗ |
| 2022-FY | $10M | $43M | $20M+ $66M short-term inv. | $14M-$54M operating cash flow | report ↗ |
| 2021-FY | $11M | $35M | $41M+ $76M short-term inv. | $11M-$38M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($5K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-07 | Dentzer James E · director, President & CEO | Award / grant (derivative) | 110,090 | $5.29 | $582K | Form 4 |
| 2026-07-07 | Zung Jonathan B. · CDO | Award / grant (derivative) | 48,285 | $5.29 | $255K | Form 4 |
| 2026-07-07 | Duvall Diantha · CFO | Award / grant (derivative) | 48,285 | $5.29 | $255K | Form 4 |
| 2026-07-07 | Borgman Anne Elizabeth · director | Award / grant (derivative) | 6,800 | $5.29 | $36K | Form 4 |
| 2026-07-07 | GREENACRE MARTYN D · director | Award / grant (derivative) | 6,800 | $5.29 | $36K | Form 4 |
| 2026-07-07 | Hohneker John · director | Award / grant (derivative) | 6,800 | $5.29 | $36K | Form 4 |
| 2026-07-07 | KAITIN KENNETH I · director | Award / grant (derivative) | 6,800 | $5.29 | $36K | Form 4 |
| 2026-07-07 | Rubin Marc · director | Award / grant (derivative) | 6,800 | $5.29 | $36K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 42 reporting institutions held 15.8M shares ($8.6M, 650.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Bleichroeder LP | 3,802,329 | $2.1M |
| 2 | Stonepine Capital Management, LLC | 3,726,406 | $2.0M |
| 3 | Nantahala Capital Management, LLC | 2,000,000 | $1.1M |
| 4 | SPHERA FUNDS MANAGEMENT LTD. | 1,994,937 | $1.1M |
| 5 | Cable Car Capital, LP | 1,333,334 | $730K |
| 6 | Dauntless Investment Group, LLC | 658,725 | $362K |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 374,326 | $205K |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 366,740 | $201K |
| 9 | M28 Capital Management LP | 284,889 | $156K |
| 10 | MORGAN STANLEY | 254,245 | $139K |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 168,327 | $92K |
| 12 | CM Management, LLC | 150,000 | $82K |
| 13 | Focused Wealth Management, Inc | 109,746 | $60K |
| 14 | CITADEL ADVISORS LLC | 67,018 | $37K |
| 15 | BOOTHBAY FUND MANAGEMENT, LLC | 62,168 | $34K |